Format

Send to

Choose Destination
EMBO J. 2004 Jul 21;23(14):2707-12. Epub 2004 Jul 1.

Defective downregulation of receptor tyrosine kinases in cancer.

Author information

1
Department of Biochemistry, Norwegian Radium Hospital, Montebello, Oslo, Norway.

Abstract

Most growth factors control cellular functions by activating specific receptor tyrosine kinases (RTKs). While overactivation of RTK signalling pathways is strongly associated with carcinogenesis, it is becoming increasingly clear that impaired deactivation of RTKs may also be a mechanism in cancer. A major deactivation pathway, receptor downregulation, involves ligand-induced endocytosis of the RTK and subsequent degradation in lysosomes. A complex molecular machinery that uses the small protein ubiquitin as a key regulator assures proper endocytosis and degradation of RTKs. Here we discuss evidence that implicates deregulation of this machinery in cancer.

PMID:
15229652
PMCID:
PMC514952
DOI:
10.1038/sj.emboj.7600292
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center